Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad) Free MOR Stock Alerts

MorphoSys (MOR) News Today

MorphoSys logo
$18.96 0.00 (0.00%)
As of 07/11/2025
Compare

MOR Latest News

2seventy bio (NASDAQ:TSVT) and MorphoSys (NASDAQ:MOR) Critical Comparison
July 4, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30199720
Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer
June 17, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/maxion-therapeutics-appoints-dr-stefan-120000645.html
Essential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsight
March 21, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/31518365/essential-thrombocythemia-market-set-for-significant-growth-across-7mm-delveinsight/
Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts
February 12, 2025  |  seekingalpha.comhttps://seekingalpha.com/news/4406332-royalty-pharma-targets-3b-share-buyback-and-projects-4minus-9-percent-growth-in-2025
Novartis shutters MorphoSys sites, lays off staff
December 19, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/novartis-shutters-morphosys-sites-lays-121200979.html
Some 330 jobs hit as Novartis closes Morphosys, WiWo reports
December 19, 2024  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/some-330-jobs-hit-novartis-closes-morphosys-wiwo-reports-2024-12-19/
Novartis raises mid-term sales guidance
November 21, 2024  |  seekingalpha.comhttps://seekingalpha.com/news/4316088-novartis-raises-mid-term-sales-guidance
Novartis: launch of Morphosys drug by could be 2027 or later
November 21, 2024  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/novartis-launch-morphosys-drug-by-could-be-2027-or-later-2024-11-21/
Idiopathic Membranous Nephropathy Market Size is estimated to grow with a significant CAGR during the study period (2020-2034).
November 14, 2024  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/29586487/idiopathic-membranous-nephropathy-market-size-is-estimated-to-grow-with-a-significant-cagr-during-the-study-period-2020-2034/
Tango stock plunges 28% amid pipeline updates, Q3 earnings report
November 6, 2024  |  msn.comhttps://www.msn.com/en-us/money/markets/tango-stock-plunges-28-amid-pipeline-updates-q3-earnings-report/ar-AA1tCtGZ
Myrobalan Therapeutics Strengthens Board of Directors with Appointment of Emma Reeve
October 16, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/myrobalan-therapeutics-strengthens-board-directors-110000165.html
Biogen: Felzartamab Receives Breakthrough Therapy Designation - Quick Facts
October 9, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/biogen-felzartamab-receives-breakthrough-therapy-designation-quick-facts-1033831487
Novartis Stock: Resilient Performance Amid Market Volatility
October 8, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-10/63462317-novartis-stock-resilient-performance-amid-market-volatility-660.htm
EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy
September 26, 2024  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2024/09/26/10079276.htm
Novartis Pharma AG: FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
September 17, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-09/63284986-novartis-pharma-ag-fda-approves-novartis-kisqali-to-reduce-risk-of-recurrence-in-people-with-hr-her2-early-breast-cancer-399.htm
MorphoSys AG: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
August 27, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-08/63101487-morphosys-ag-merger-squeeze-out-of-morphosys-minority-shareholders-approved-at-2024-annual-general-meeting-200.htm
EQS-News: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
August 27, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/eqs-news-merger-squeeze-out-of-morphosys-minority-shareholders-approved-at-2024-annual-general-meeting-1033725930
MorphoSys (MOR) Set to Announce Earnings on Thursday
August 22, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-earnings-date-2024-08-22/
MORF Apr 2025 62.500 call(CONTR (MORF250417C00062500)
August 18, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/MORF250417C00062500/
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
August 15, 2024  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2024/08/15/incyte-announces-positive-topline-results-from-pivotal-study-of-tafasitamab
MorphoSys AG (MORD.XC)
August 13, 2024  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/quote/MORD.XC/risk/
MorphoSys AG (1MOR.MI)
August 12, 2024  |  sg.finance.yahoo.comhttps://sg.finance.yahoo.com/chart/1MOR.MI
Royalty Pharma Reports Second Quarter 2024 Results
August 8, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/royalty-pharma-reports-second-quarter-2024-results-1033659937
Xencor Reports Second Quarter 2024 Financial Results
August 6, 2024  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2024/08/05/xencor-reports-second-quarter-2024-financial-results
European Equities Traded in the US as American Depositary Receipts Plunge in Monday Trading
August 5, 2024  |  msn.comhttps://www.msn.com/en-us/money/companies/european-equities-traded-in-the-us-as-american-depositary-receipts-plunge-in-monday-trading/ar-AA1ogJV9
Leerink Partnrs Analysts Boost Earnings Estimates for MorphoSys AG (NASDAQ:MOR)
July 29, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-analyst-earnings-estimates-2024-07-29/
EVPassport Announces Opening of East Coast Headquarters in Boston and Key Executive Appointments Amidst Rapid Growth
July 25, 2024  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2024/07/25/10047998.htm
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG – MOR
July 16, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/07/16/2914184/0/en/shareholder-alert-the-m-a-class-action-firm-investigates-tender-offer-expiring-august-2-2024-of-morphosys-ag-mor.html
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG - MOR
July 15, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-investigates-tender-offer-expiring-august-2-2024-of-morphosys-ag--mor-302197140.html
Susquehanna International Securities Ltd. Cuts Position in MorphoSys AG (NASDAQ:MOR)
July 14, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-sec-filing-2024-07-14/
MorphoSys: Novartis Deal Is All But Done
July 8, 2024  |  seekingalpha.comhttps://seekingalpha.com/article/4702905-morphosys-stock-mor-novartis-deal-all-but-done
Hennion & Walsh Asset Management Inc. Has $2.12 Million Position in MorphoSys AG (NASDAQ:MOR)
June 29, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-sec-filing-2024-06-29/
Short Interest in MorphoSys AG (NASDAQ:MOR) Decreases By 65.0%
June 27, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-options-data-report-2024-06-27/
MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders
June 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240620648176/en/mor-stock-alert-halper-sadeh-llc-is-investigating-whether-the-sale-of-morphosys-ag-is-fair-to-shareholders/
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority Shareholders
June 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240619218783/en/morphosys-and-novartis-sign-delisting-agreement-and-intend-to-implement-a-merger-squeeze-out-of-morphosys%e2%80%99-minority-shareholders/
Opaleye Management Inc. Has $1.44 Million Stock Holdings in MorphoSys AG (NASDAQ:MOR)
June 15, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-sec-filing-2024-06-15/
4,234,685 Shares in MorphoSys AG (NASDAQ:MOR) Bought by Kynam Capital Management LP
June 10, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-sec-filing-2024-06-10/
MorphoSys AG (NASDAQ:MOR) Receives Consensus Recommendation of "Hold" from Brokerages
June 9, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-consensus-analyst-rating-2024-06-09/
MorphoSys AG (NASDAQ:MOR) Shares Purchased by TD Asset Management Inc
June 7, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-sec-filing-2024-06-07/
Monoclonal Antibody May Benefit Patients With Kidney Transplant Rejection
May 28, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/monoclonal-antibody-may-benefit-patients-with-kidney-transplant-rejection/ar-BB1ndxeo
Novartis releases Phase III data on its investigational oral therapy to treat chronic kidney disease
May 27, 2024  |  msn.comhttps://www.msn.com/en-in/health/health-news/novartis-releases-phase-iii-data-on-its-investigational-oral-therapy-to-treat-chronic-kidney-disease/ar-BB1n6FaK
MorphoSys (MOR) Scheduled to Post Earnings on Monday
May 26, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-earnings-date-2024-05-26/
Novartis Pharma AG: Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
May 16, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-05/62250463-novartis-pharma-ag-novartis-meets-all-tender-offer-conditions-to-acquire-morphosys-ag-for-eur-68-per-share-in-cash-399.htm
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
May 16, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/novartis-meets-tender-offer-conditions-092700927.html
Novartis Meets Offer Conditions To Buy MorphoSys In EUR 68/shr Cash Deal
May 16, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/novartis-meets-offer-conditions-to-buy-morphosys-in-eur-68-shr-cash-deal-1033392021
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
May 16, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/16/2883195/0/en/novartis-meets-all-tender-offer-conditions-to-acquire-morphosys-ag-for-eur-68-per-share-in-cash.html
MorphoSys AG (NASDAQ:MOR) Receives Consensus Recommendation of "Hold" from Analysts
May 15, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-consensus-analyst-rating-2024-05-15/
MorphoSys (NASDAQ:MOR) Sets New 1-Year High at $18.38
May 14, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-52-week-high-2024-05-14/
Short Interest in MorphoSys AG (NASDAQ:MOR) Decreases By 18.3%
May 13, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nasdaq-mor-options-data-report-2024-05-13/
MorphoSys (ETR:MOR) shareholders have earned a 228% return over the last year
May 10, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/morphosys-etr-mor-shareholders-earned-061505236.html?.tsrc=rss
Get MorphoSys News Delivered to You Automatically

Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

MOR Media Mentions By Week

MOR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MOR
News Sentiment
▼
0.00

1.01
▲
Average
Medical
News Sentiment

MOR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MOR Articles
This Week
▼
0

0
▲
MOR Articles
Average Week

Get MorphoSys News Delivered to You Automatically

Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:MOR) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...
Paradigm Press | Sponsored
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...
Golden Portfolio | Sponsored
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Banks aren’t ready for this altcoin—are you?
Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...
Crypto 101 Media | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored